According to the Zhitong Finance App, Shisi Pharmaceutical Group (02005.HK) announced that the group has obtained drug production registration approval from the China National Drug Administration for sodium glycerophosphate injection (10ml: 2.16g), which is a category 4 chemical drug. It is considered to have passed the consistency evaluation, and is the third domestic company to be approved. Sodium glycerophosphate injection is a nutritional medicine, mainly used as a phosphorus supplement for parenteral nutrition in adults and for patients with phosphorus deficiency.

According to the Zhitong Finance App, Shisi Pharmaceutical Group (02005.HK) announced that the group has obtained drug production registration approval from the China National Drug Administration for sodium glycerophosphate injection (10ml: 2.16g), which is a category 4 chemical drug. It is considered to have passed the consistency evaluation, and is the third domestic company to be approved. Sodium glycerophosphate injection is a nutritional medicine, mainly used as a phosphorus supplement for parenteral nutrition in adults and for patients with phosphorus deficiency.